A lack of demonstrated clinical benefit precludes radiotherapy (RT) from being recommended for pN1/pN2 penile cancer (PeCa) lesions; but it may be recommended in case of extranodal (pN3) disease or for positive resection margins.
Intravesical bacillus Calmette-Guérin (BCG) therapy is standard treatment for high-risk non-muscle invasive bladder cancer (NMIBC) but overall efficacy is low, and no reliable predictive biomarkers currently exist to refine patient selection.
Bladder cancer invasion depends on mammalian target of rapamycin complex-2 (mTORC2) activity, although the downstream mTORC2 effectors that mediate this effect have not been fully defined. One potential downstream effector is the arginine derivative nitric oxide (NO).
Ashish Kamat: Hello everyone. And welcome to UroToday’s Bladder Cancer Center of Excellence. I’m Ashish Kamat, Professor of Urologic Oncology and Cancer Research at MD Anderson Cancer Center in Houston, Texas. And it is my pleasure to welcome today a who’s who cadre of superstars when it comes to bladder cancer. We have with us, […]
Non-muscle-invasive bladder cancers (NMIBC) represent a heterogeneous group of tumors with variable clinical outcomes. Multiple risk features are incorporated in predicting the risk of recurrence and progression to muscle-invasive bladder cancer (MIBC). Intravesical immunotherapy with Bacillus Calmette-Guerin (BCG) and chemotherapy are both considered adjuvant treatment options. However, it is challenging to define the optimum adjuvant […]
Objectives: To determine which flexible ureterorenoscopy program would be most cost-efficient in our center, a cost efficiency analysis and a formula to assess cost efficiency feasibility of a hybrid model were performed. Methods: Total cost per case of reusable flexible ureterorenoscopes (rfURS) was retrospectively calculated and compared with two single-use flexible ureterorenoscopes (sufURS) marketed. A mathematical formula was […]
San Francisco, CA (UroToday.com) — The Prostate Cancer Foundation (PCF), the world’s leading philanthropic organization dedicated to funding life-saving prostate cancer research, announced that Charles (Chuck) J. Ryan, MD, an internationally recognized genitourinary (GU) oncologist with expertise in the biology and treatment of advanced prostate cancer, has been appointed President and Chief Executive Officer.
Every September, the EAU hosts Urology Week, an international campaign for increasing awareness of urological conditions and treatment. This year, Urology Week (20-24 September 2021) will focus its attention on incontinence. Based on the latest information, about 20% of adults have had some experience with incontinence. Yet, many people don’t seek help or talk to […]
Renal cell carcinoma is a common malignant tumour, whose incidence is steadily increasing. Whilst operative techniques have recently improved, including possibilities of renal preservation and minimally invasive surgery, no use has been shown for adjuvant treatment strategies.
To test for the impact of patient comorbidities and medical risk factors on kidney function after partial (PN) or radical nephrectomy (RN) in renal cell carcinoma (RCC) patients with normal preoperative renal function.
